Acute Leukemia Working Party (ALWP)
Study type:
Study number:
8421193
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Acute Myeloid Leukaemia (AML)
Short title:
Primary objective:
This study is a retrospective registry-based analysis to study and role/prognostic impact of pre -alloSCT MRD in patients with AML in complete remission undergoing allogeneic transplantation from unrelated donor with post transplantation cyclophosphamide as GVHD prophylaxis.
Key inclusion criteria:
• de-novo AML
• adults, age ≥ 18 years
• Transplant dates 2010-2018
• HLA 10/10 matched unrelated donors (if we need more numbers we include 9/10)
• PBSC or bone-marrow as the stem cell source
• CR1 at the time of transplantation
• Myeloablative or Reduced- intensity conditioning
• Receiving PTCy as GVHD prophylaxis
• Available MRD tests prior to transplantation
• adults, age ≥ 18 years
• Transplant dates 2010-2018
• HLA 10/10 matched unrelated donors (if we need more numbers we include 9/10)
• PBSC or bone-marrow as the stem cell source
• CR1 at the time of transplantation
• Myeloablative or Reduced- intensity conditioning
• Receiving PTCy as GVHD prophylaxis
• Available MRD tests prior to transplantation
Country:
Israel
Principal investigator:
Arnon Nagler